期刊
JOURNAL OF PATHOLOGY
卷 223, 期 2, 页码 262-273出版社
WILEY
DOI: 10.1002/path.2789
关键词
Notch signalling; oncogene; T-cell lymphoblastic leukaemia/lymphoma; chromosomal rearrangements; targeted therapy
资金
- National Institute of Health [P01CA119070, R01CA092433, R01AI047833, P01CA 119070]
- Leukemia and Lymphoma Society
- NATIONAL CANCER INSTITUTE [R01CA092433, P01CA119070] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047833] Funding Source: NIH RePORTER
Notch receptors participate in a highly conserved signalling pathway that regulates normal development and tissue homeostasis in a context-and dose-dependent manner. Deregulated Notch signalling has been implicated in many diseases, but the clearest example of a pathogenic role is found in T-cell lymphoblastic leukaemia/lymphoma (T-LL), in which the majority of human and murine tumours have acquired mutations that lead to aberrant increases in Notch1 signalling. Remarkably, it appears that the selective pressure for Notch mutations is virtually unique among cancers to T-LL, presumably reflecting a special context-dependent role for Notch in normal T-cell progenitors. Nevertheless, there are some recent reports suggesting that Notch signalling has subtle, yet important roles in other forms of haematological malignancy as well. Here, we review the role of Notch signalling in various blood cancers, focusing on T-LL with an eye towards targeted therapeutics. Copyright (C) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据